Source: dvm360

The FDA has granted support for the development of LOY-001, a drug aimed at extending the lifespan and improving the quality of life for large- and giant-breed dogs. Loyal, the biotech company behind the drug, received approval for the “Reasonable Expectation of Effectiveness” section of its conditional approval application. While LOY-001 itself has not been approved, this support marks a significant milestone in the development process.

The drug targets insulin-like growth factor 1 (IGF-1), a hormone associated with cell growth, believed to contribute to the shorter lifespan of large dogs. Loyal anticipates making LOY-001 available in the veterinary pharmaceutical market by 2026, with a focus on affordability for pet owners. The drug represents a new category focusing on mechanisms of aging to prevent age-associated diseases.

Read the full story HERE: